Complete Genome Sequence of the Lumpy Skin Disease Virus Isolated from the First Reported Case in Greece in 2015

Agianniotaki, Eirini I.; Mathijs, Élisabeth; Vandenbussche, Frank; Tasioudi, Konstantia E.; Haegeman, Andy; Iliadou, Peristera; Chaintoutis, Serafeim C.; Dovas, Chrysostomos Ι.; Borm, Steven Van; Chondrokouki, Eleni; Clercq, Kris De

doi:10.1128/genomea.00550-17

Cited by 41 publications

(41 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…• Identification of the vaccine virus in five vaccinated animals (Agianniotaki et al, 2017); • Demonstration of LSD vaccine DNA in blood, skin lesions, milk and saliva from vaccinated cows. (Bedekovic et al, 2017); • Decrease in milk production (RM65 vaccine) (Abutarbush and Tuppurainen, 2018); • Various reports on adverse effects, collected by passive surveillance (EFSA, 2019);…”

Section: Side Effects Of Vaccination: Survey In Israelmentioning

confidence: 99%

Lumpy skin disease epidemiological report IV: data collection and analysis

Calistri¹,

Clercq²,

Gubbins³

et al. 2020

EFS2

Self Cite

View full text Add to dashboard Cite

In 2019, no lumpy skin disease (LSD) outbreaks were reported in South‐Eastern Europe, the mass vaccination regional campaign with homologous LSD vaccine continued for the fourth year with over 1.8 million bovines vaccinated in the region, preventing further outbreaks since 2016. LSD outbreaks were reported in Turkey, including western Turkey, in Russia and in eastern Asia affecting China, Bangladesh and India for the first time. The use of homologous vaccine should be considered in the countries still affected in order to eliminate the virus. Besides passive surveillance, which is implemented in all the countries, active surveillance for early detection based on clinical examination could be conducted ideally during April–October every 5 weeks in at‐risk areas, based on possible re‐emergence or re‐introduction from affected neighbouring countries. Active surveillance for proving disease freedom could be based on serological testing (enzyme‐linked immunosorbent assay (ELISA)) targeting 3.5% seroprevalence and conducted on a random sample of cattle herds on non‐vaccinated animals. LSD re‐emerged in Israel in 2019, after vaccination became voluntary. This shows that, if the virus is still circulating in the region, the reduced protection might result in re‐emergence of LSD. In case of re‐emergence, a contingency plan and vaccine stockpiling would be needed, in order to react quickly. From a study performed in Israel to test side effects of live‐attenuated homologous LSD vaccine, milk production can be reduced during 7 days after vaccination (around 6–8 kg per cow), without a significant loss in the 30 days after vaccination. Research needs should be focused on the probability of transmission from insect to bovine, the virus inactivation rate in insects, the collection of baseline entomological data, the capacity of vector species in LSDV transmission linked to studies on their abundance and the control of Stomoxys calcitrans being the most important vector in LSD transmission.

show abstract

Section: Side Effects Of Vaccination: Survey In Israelmentioning

confidence: 99%

Lumpy skin disease epidemiological report IV: data collection and analysis

Calistri¹,

Clercq²,

Gubbins³

et al. 2020

EFS2

Self Cite

View full text Add to dashboard Cite

show abstract

“…The DNA was extracted from a skin lesion using the Puregene core kit A (Qiagen) as previously described (3). Presequencing enrichment was performed through 23 PCR amplicons (7,417 to 7,852 bp) with 1-kb overlaps covering the entire genome as described previously (4, 5) using the Q5 high-fidelity DNA polymerase (New England BioLabs).…”

mentioning

confidence: 99%

Complete Coding Sequence of a Lumpy Skin Disease Virus Strain Isolated during the 2016 Outbreak in Kazakhstan

Mathijs

Vandenbussche

Saduakassova

et al. 2020

Microbiol Resour Announc

Self Cite

View full text Add to dashboard Cite

show abstract

“…A number of studies reporting adverse effects of vaccination have been published recently (Agianniotaki et al., ; Bedekovic et al., ; Abutarbush and Tuppurainen, ; Katsoulos et al., ).…”

Section: Assessmentmentioning

confidence: 99%

“…A number of studies reporting adverse effects of vaccination have been published recently (Agianniotaki et al, 2017;Bedekovic et al, 2017;Abutarbush and Tuppurainen, 2018;Katsoulos et al, 2018). Agianniotaki et al (2017) carried out sequence comparisons of LSDV found in field samples from three unvaccinated animals originating from different geographical regions in Greece (northern, central and southern Greece), along with 10 additional nodular samples, which were obtained from vaccinated animals (vaccinated with either LSD Vaccine for Cattle, Onderstepoort Biological Products; OBP, South Africa or Lumpyvax, MSD Animal Health-Intervet, South Africa) presenting LSD clinical signs. The vaccine virus was identified in five of the vaccinated animals.…”

Section: Safety Of Vaccination Against Lsd: Literature Reviewmentioning

confidence: 99%

Lumpy skin disease

Calistri¹,

DeClercq²,

Gubbins³

et al. 2019

EFS2

View full text Add to dashboard Cite

In 2018, no lumpy skin disease (LSD) outbreaks were reported in the Balkan region, after the decline reported in 2017 (385) compared to 2016 (7,483). This confirms the effectiveness of the vaccination campaign based on the LSD homologous vaccine strain which continued throughout 2018 with over 2.5 million animals vaccinated, keeping the mean vaccination coverage above 70%. In 2018, LSD outbreaks were reported in Russia, Turkey and Georgia. In Russia, the LSD epidemics expanded northward and eastward, while in Turkey, the most affected region was in the east. LSD is spreading in Turkey since 2013, despite large vaccination campaigns with heterologous vaccine performed since 2014. This might support the hypothesis that the use of heterologous vaccines results in insufficient protection, and therefore, the use of homologous LSD vaccine in Turkey should be considered to prevent further spread. As the LSD epidemic in Turkey is a risk for reintroduction into the EU, it is recommended to continue the vaccination campaigns in 2019 in the high‐risk areas of Balkan region. Spread rates of LSD within a village were estimated from outbreak data for Albania, which can be used to inform the level of vaccination required to control an outbreak in a village. In terms of vaccine safety, the reports from the field suggest that, compared to the large number of animals vaccinated in the Balkan region since 2015, a very limited number of side effects have been recorded so far, although from published literature, local or even systemic side effects in some animals may occur after vaccination. However, due to inadequate study design in the reviewed studies, there is no consensus on the magnitude of such effects and on their real consequences on production.

show abstract

Complete Genome Sequence of the Lumpy Skin Disease Virus Isolated from the First Reported Case in Greece in 2015

Cited by 41 publications

References 7 publications

Lumpy skin disease epidemiological report IV: data collection and analysis

Lumpy skin disease epidemiological report IV: data collection and analysis

Complete Coding Sequence of a Lumpy Skin Disease Virus Strain Isolated during the 2016 Outbreak in Kazakhstan

Lumpy skin disease

Contact Info

Product

Resources

About